Latest Listings And Ipos News

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

iTech Minerals has confirmed it will soon announce new high-grade antimony findings at its Reynold Range Project, following a notable uptick in its share price and trading volume.

Star Minerals Limited addresses a sharp rise in its share price and trading volume, attributing the movement to pending assay results from recent drilling activities. The company confirms compliance with ASX disclosure rules while preparing to release interpreted data.

Mammoth Minerals has finalized its acquisition of two promising US gold projects and revamped its leadership to spearhead a high-grade gold drilling campaign.

Andromeda Metals has addressed recent share price gains and trading volume spikes, attributing the activity to ongoing funding efforts and strategic project studies rather than undisclosed information.

Tombador Iron Limited is set to transform itself by acquiring GoviEx Uranium, creating a new ASX-listed uranium company focused on Zambia’s Muntanga Project. This deal includes a significant capital raise and board overhaul, aiming for a November 2025 completion.

Challenger Limited reported a robust FY25 with a 9% rise in normalised profit and a strategic push into digital transformation and retirement income solutions.

Challenger Limited celebrates four decades with a robust 9% rise in net profit and a strategic digital transformation, positioning itself at the forefront of Australia’s retirement income market.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

HMC Capital reported a robust FY25 with a 51% rise in operating EPS and a 47% jump in assets under management to $18.7 billion, driven by expansion across multiple funds management divisions.